Advanced search
Publication Cover
Journal of Medical Economics Volume 13, 2010 - Issue 2
Submit an article Journal homepage
581
Views
14
CrossRef citations to date
0
Altmetric
Original Article

Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise

Saku Torvinen GlaxoSmithKline, Espoo, FinlandCorrespondence[email protected]
,
Pekka Nieminen University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki, Finland
,
Matti Lehtinen National Public Health Institute, Oulu, Finland
,
Jorma Paavonen University of Helsinki, Department of Obstetrics and Gynaecology, Helsinki, Finland
,
Nadia Demarteau GlaxoSmithKline Biologicals, Rixensart, Belgium
&
Jarmo Hahl Abbott, Espoo, Finland
Pages 284-294 | Published online: 18 May 2010

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Wadie Messoudi, Toufik Elmahi, Chakib Nejjari, Nabil Tachfouti, Ahmed Zidouh, Ghali Saadani, David Moriña & Mireia Diaz. (2019) Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. Journal of Medical Economics 22:11, pages 1153-1159.
Read now
Dimitris Kostaras, Eleftheria Karampli & Kostas Athanasakis. (2019) Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries. Expert Review of Pharmacoeconomics & Outcomes Research 19:2, pages 147-158.
Read now
Allex Jardim Fonseca & Luiz Carlos de Lima Ferreira. (2014) Systematic review of the cost-effectiveness of the vaccination against HPV in Brazil. Human Vaccines & Immunotherapeutics 10:12, pages 3484-3490.
Read now

Articles from other publishers (11)

Anton Barchuk, Alexander Bespalov, Heini Huhtala, Tuvshinjargal Chimed, Irina Laricheva, Alexey Belyaev, Freddie Bray, Ahti Anttila & Anssi Auvinen. (2018) Breast and cervical cancer incidence and mortality trends in Russia 1980–2013. Cancer Epidemiology 55, pages 73-80.
Crossref
Leonardo Simonella & Karen Canfell. (2015) Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries. Vaccine 33:1, pages 34-51.
Crossref
Allex Jardim da Fonseca, Luiz Carlos de Lima Ferreira & Giacomo Balbinotto Neto. (2013) Cost-effectiveness of the vaccine against human papillomavirus in the Brazilian Amazon region. Revista da Associação Médica Brasileira 59:5, pages 442-451.
Crossref
Péter Bősze. (2013) The first vaccine against cancer: the human papillomavirus vaccine. Orvosi Hetilap 154:16, pages 603-618.
Crossref
Zoltán Vokó, László Nagyjánosi & Zoltán Kaló. (2012) Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health 12:1.
Crossref
Katherine Seto, Fawziah Marra, Adam Raymakers & Carlo A. Marra. (2012) The Cost Effectiveness of Human Papillomavirus Vaccines. Drugs 72:5, pages 715-743.
Crossref
Katherine A. Lyseng-Williamson & Kate McKeage. (2012) AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): a guide to its use. Drugs & Therapy Perspectives 28:3, pages 1-6.
Crossref
Stephen P. Tully, Andrea M. Anonychuk, Diana Maria Sanchez, Alison P. Galvani & Chris T. Bauch. (2012) Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. Vaccine 30:2, pages 425-435.
Crossref
Yin Ling Woo & Siti Z. Omar. (2011) Human papillomavirus vaccination in the resourced and resource-constrained world. Best Practice & Research Clinical Obstetrics & Gynaecology 25:5, pages 597-603.
Crossref
Kate McKeage & Barbara Romanowski. (2011) Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)†. BioDrugs 25:4, pages 265-269.
Crossref
E.J.O. Soini, J.A. Martikainen & T. Nousiainen. (2011) Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Annals of Oncology 22:5, pages 1189-1197.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.